NASDAQ:ATRS - Antares Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.65 -0.04 (-1.49 %)
(As of 07/16/2018 12:24 PM ET)
Previous Close$2.68
Today's Range$2.63 - $2.68
52-Week Range$1.58 - $4.09
Volume9,666 shs
Average Volume702,997 shs
Market Capitalization$421.86 million
P/E Ratio-24.45
Dividend YieldN/A
Beta0.22
Antares Pharma logoAntares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector II needle-free auto injectors to administer human growth hormone for patients with growth retardation; and VIBEX disposable pressure-assisted auto injectors. In addition, the company develops XYOSTED for the treatment of testosterone deficiency in adult males; VIBEX auto injectors for treating anaphylaxis; and disposable pen injectors for diabetes and osteoporosis. It has strategic alliances with Teva Pharmaceutical Industries, Ltd. and AMAG Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.

Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ATRS
CUSIP03664210
Phone609-359-3020

Debt

Debt-to-Equity Ratio0.88
Current Ratio2.94
Quick Ratio2.39

Price-To-Earnings

Trailing P/E Ratio-24.45
Forward P/E Ratio-33.13
P/E GrowthN/A

Sales & Book Value

Annual Sales$54.51 million
Price / Sales7.62
Cash FlowN/A
Price / CashN/A
Book Value$0.21 per share
Price / Book12.62

Profitability

EPS (Most Recent Fiscal Year)($0.11)
Net Income$-16,740,000.00
Net Margins-32.96%
Return on Equity-52.74%
Return on Assets-23.67%

Miscellaneous

Employees111
Outstanding Shares156,830,000
Market Cap$421.86

The Truth About Cryptocurrencies

Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

How were Antares Pharma's earnings last quarter?

Antares Pharma Inc (NASDAQ:ATRS) posted its quarterly earnings data on Tuesday, May, 8th. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.01. The specialty pharmaceutical company earned $12.70 million during the quarter, compared to analysts' expectations of $12.85 million. Antares Pharma had a negative return on equity of 52.74% and a negative net margin of 32.96%. View Antares Pharma's Earnings History.

What price target have analysts set for ATRS?

2 brokerages have issued 1 year target prices for Antares Pharma's stock. Their predictions range from $3.00 to $4.00. On average, they expect Antares Pharma's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 32.1% from the stock's current price. View Analyst Ratings for Antares Pharma.

What is the consensus analysts' recommendation for Antares Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Antares Pharma's key competitors?

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the folowing people:
  • Mr. Robert F. Apple, CEO, Pres & Director (Age 52)
  • Mr. Fred M. Powell, Exec. VP & CFO (Age 57)
  • Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 51)
  • Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. and Corp. Controller (Age 55)
  • Edward Kessig, VP of Sales

Has Antares Pharma been receiving favorable news coverage?

News coverage about ATRS stock has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Antares Pharma earned a media sentiment score of 0.09 on Accern's scale. They also assigned news stories about the specialty pharmaceutical company an impact score of 48.13 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $2.65.

How big of a company is Antares Pharma?

Antares Pharma has a market capitalization of $421.86 million and generates $54.51 million in revenue each year. The specialty pharmaceutical company earns $-16,740,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Antares Pharma employs 111 workers across the globe.

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]


MarketBeat Community Rating for Antares Pharma (NASDAQ ATRS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  233 (Vote Outperform)
Underperform Votes:  157 (Vote Underperform)
Total Votes:  390
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe ATRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.